8-K: Privia Health Soars in Q3 2025, Raises Full-Year Guidance

Privia Health Group, Inc. reported very strong third quarter and year-to-date 2025 financial results, with significant growth in net income and adjusted EBITDA, leading to an upward revision of its full-year guidance.

Summary

• Net Income for the third quarter ended September 30, 2025, increased 94.1% to $6.9 million compared to $3.5 million in Q3 2024.
• Adjusted EBITDA for Q3 2025 grew 61.6% to $38.2 million, up from $23.6 million in Q3 2024.
• Implemented Providers reached 5,250, a 13.1% increase compared to Q3 2024.
• Practice Collections for Q3 2025 were $940.4 million, representing a 27.1% increase over $739.9 million in Q3 2024.
• Value-Based Care Attributed Lives increased 12.8% to 1,406,000 as of September 30, 2025.
• For the nine months ended September 30, 2025, total revenue was $1,581.7 million (+24.0% vs YTD 2024) and Adjusted EBITDA was $94.1 million (+43.5% vs YTD 2024).
• Privia's Accountable Care Organizations (ACOs) achieved aggregate shared savings of $234.1 million in the Medicare Shared Savings Program (MSSP) for the 2024 performance year, a 32.6% increase from 2023.
• The company signed a definitive agreement on September 23, 2025, to acquire an ACO business from Evolent Health, Inc. for $100 million in cash at closing, plus up to an additional $13 million, which will add over 120,000 attributed lives.
• Full-year 2025 guidance was raised above the high end for all key operating and financial metrics, including Adjusted EBITDA now projected between $118 million and $121 million.

Sentiment

Score: 9

Explanation: The filing reports exceptionally strong financial and operational results, significantly exceeding prior year performance and leading to an upward revision of full-year guidance. The strategic acquisition further enhances future growth prospects in value-based care. The company maintains a strong cash position with no debt.

Positives

• Net Income for Q3 2025 increased 94.1% to $6.9 million.
• Adjusted EBITDA for Q3 2025 increased 61.6% to $38.2 million.
• Implemented Providers grew 13.1% to 5,250.
• Practice Collections increased 27.1% to $940.4 million.
• Value-Based Care Attributed Lives grew 12.8% to 1,406,000.
• Strong MSSP 2024 performance with $234.1 million in aggregate shared savings, up 32.6% from 2023.
• Strategic acquisition of an ACO business from Evolent Health, Inc., expanding VBC footprint to over 1.5 million attributed lives.
• Raised full-year 2025 guidance for all key operating and financial metrics, including Implemented Providers (5,300-5,350), Attributed Lives (1,400,000-1,425,000), Practice Collections ($3,450-$3,500 million), GAAP Revenue ($2,050-$2,100 million), Care Margin ($455-$460 million), Platform Contribution ($230-$235 million), and Adjusted EBITDA ($118-$121 million).
• Strong balance sheet with $441.4 million cash and no debt at September 30, 2025.
• Expects to end FY25 with at least $410 million in cash and equivalents pro forma for the ACO transaction.
• More than 80% of Adjusted EBITDA expected to convert to free cash flow in full-year 2025.

Negatives

• Net cash used in investing activities for the nine months ended September 30, 2025, was $90.3 million, primarily due to business acquisitions.
• Non-cash stock compensation expense was $19.0 million in Q3 2025 and $55.6 million YTD 2025, which impacts GAAP net income.

Risks

• Operating in a heavily regulated industry, with potential failure to comply with extensive applicable healthcare laws and government regulations.
• Complexity of the legal framework governing relationships with Medical Groups (some not owned) and Privia providers, and the impact of legal challenges or shifting interpretations of applicable laws.
• Execution of the growth strategy may not prove viable, and expected results may not be realized.
• Difficulties in timely implementing the proprietary end-to-end, cloud-based technology solution for Privia physicians and new medical groups.
• High level of competition in the industry.
• Challenges in successfully establishing a presence in new geographic markets.
• Impact of failures by or service disruptions at key third-party vendors, such as the primary electronic medical record vendor, athenahealth, Inc.
• Potential decreases in reimbursement rates by governmental and third-party payers, changes to payment terms, or challenges negotiating and retaining favorable contracts with private third-party payers, and changes impacting the patient population.
• Financial and operational impact of compliance with various complex and changing federal and state privacy and security laws and regulations, including HIPAA.
• Impact of actual and potential security threats, cybersecurity incidents, or privacy or other forms of data breaches involving the company, its vendors, or other third parties.
• Continued availability of qualified workforce, including staff at medical groups, and continued upward pressure on compensation for such workforce.

Future Outlook

Privia Health raised its full-year 2025 guidance above the high end for all key operating and financial metrics, including Adjusted EBITDA projected to be between $118 million and $121 million. The company expects more than 80% of Adjusted EBITDA to convert to free cash flow and anticipates ending FY25 with at least $410 million in cash and equivalents pro forma for the Evolent ACO transaction. The acquisition of the Evolent ACO business is expected to close in the fourth quarter of 2025 and positively contribute to Adjusted EBITDA in 2026.

Management Comments

• The company delivered very strong third quarter and year-to-date performance across the business.
• Continued strength in same-store growth and new provider additions.
• Strong sales and business development pipeline.
• Privia's Accountable Care Organizations delivered strong 2024 performance results for the Medicare Shared Savings Program.
• The strategic acquisition of the ACO business from Evolent Health will increase VBC attributed lives in existing and new states, offering compelling synergy opportunities.
• The company is confident in its ability to convert more than 80% of Adjusted EBITDA to free cash flow in full-year 2025.

Industry Context

Privia Health operates in the rapidly evolving physician enablement and value-based care sector, which is driven by the shift from fee-for-service to outcome-based reimbursement models. The strong growth in implemented providers, attributed lives, and value-based care performance, particularly in the Medicare Shared Savings Program, indicates successful execution within this trend. The acquisition of Evolent Health's ACO business further solidifies Privia's position as a leader in expanding value-based care footprints, aligning with broader industry consolidation and the pursuit of scale to manage population health more effectively and efficiently.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, increased profitability, raised guidance, and strategic expansion, potentially leading to increased share value.
• Employees/Providers: Continued growth in implemented providers suggests a stable or expanding network, potentially offering more opportunities and stability.
• Customers/Patients: Expansion of value-based care arrangements and attributed lives indicates a broader reach and commitment to improved patient outcomes and lower costs.
• Acquired ACO providers/patients: Integration into Privia's platform offers a full suite of services and technology, potentially enhancing care delivery and administrative efficiency.

Next Steps

• Closing of the acquisition of the ACO business from Evolent Health, Inc. in the fourth quarter of 2025, subject to regulatory approvals and customary closing conditions.
• Conference call on November 6, 2025, at 8:00 am ET to discuss results and management's outlook.
• Filing of the Company's Form 10-Q with the SEC.

Key Dates

Recommendation

The company has demonstrated exceptional financial performance in Q3 2025, with significant year-over-year growth in net income, adjusted EBITDA, and key operating metrics. The upward revision of full-year guidance signals strong confidence in continued momentum. The strategic acquisition of Evolent Health's ACO business further strengthens its market position in value-based care, promising future Adjusted EBITDA contributions. With a robust balance sheet, no debt, and strong free cash flow conversion, Privia Health presents a compelling investment opportunity for growth-oriented investors.

Keywords

Privia Health, PRVA, Healthcare, Physician Enablement, Value-Based Care, ACO, Medicare Shared Savings Program, Financial Results, Earnings, Q3 2025, Guidance, Acquisition, Evolent Health, Adjusted EBITDA, Net Income, Practice Collections, Attributed Lives, Implemented Providers